| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 605.1 | 626.4 |
| Profit before tax | -26.3 | -50.2 |
| Net income | -26.9 | -49.5 |
| EPS (diluted, $ a share) | $-0.15 | $-0.28 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -3.4% |
|---|---|
| Operating margin | -4.6% |
10-Q filed with the SEC, NYSE: TDOC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Teladoc Health, Inc.: key numbers
- Share price
- $8.70Close, Nov 16
- Market cap
- $1.59B
- Shares outstanding
- 182.29MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Offices & Clinics of Doctors of MedicineSIC 8011
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Teladoc Health, Inc.
All →Teladoc Health President, International Carlos Nueno Sells $271K of Stock
Carlos Nueno, President, International, sold 29,432 shares of Teladoc Health, Inc. at $9.20 a share, worth $271K in total on Nov 6, 2026. Shares held after the trade: 35,312 (-45.5%).
- Value
- $271K
- Shares
- 29,432
- Price
- $9.20
- Role
- President, International
- Holding change
- -45.5%
- Trade date
- Nov 6, 2026
Teladoc Health Financial Results
Teladoc Health reported third quarter 2026 revenue of $605.1 million, a 3% decrease year-over-year, driven by a 13% decline in its BetterHelp segment. The company narrowed its net loss to $26.9 million ($0.15 per share) compared to $49.5 million in the prior year, while adjusted EBITDA grew 14% to $79.4 million.
- Term
- Q3 2026
“We delivered third quarter results near the upper end of our guidance range for consolidated revenue and above our range for consolidated adjusted EBITDA, reflecting solid execution across our two segments.”
Chuck Divita, Chief Executive Officer of Teladoc Health
“Within the Integrated Care segment, we continue to advance our innovation agenda, including the implementation of Teladoc One with our early launch partners, while also expanding our capabilities through initiatives such as hybrid care and AI-enabled solutions.”
Chuck Divita, Chief Executive Officer of Teladoc Health
Teladoc Health Leadership Change
Adam C. Vandervoort, Chief Legal Officer and Secretary, has resigned effective November 1, 2026, citing 'good reason' under his severance agreement. He will be succeeded by Jonathan Dorfman, the current SVP of Securities & Corporate Law, while Vandervoort provides unpaid advisory services through November 2027 to assist with the transition.
Teladoc Health CEO Charles Divita III Sells $109K of Stock
Charles Divita III, CEO, sold 17,805 shares of Teladoc Health, Inc. at $6.10 a share, worth $109K in total on Sep 11, 2026. Shares held after the trade: 465,535 (-3.7%).
- Value
- $109K
- Shares
- 17,805
- Price
- $6.10
- Role
- CEO
- Holding change
- -3.7%
- Trade date
- Sep 11, 2026